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Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma and accounts for 5-10 % of 
all non-Hodgkin lymphomas (NHL). In Sweden, the incidence of NHL is 21.6 and 15.3 per 
100 000 persons for men and women, respectively, which result in almost 100-200 new MCL 
cases per year. MCL was considered an own entity in 1994 and is characterized by the gene 
translocation t(11;14)(q13;q32), CCND1/IGH ,that occurs in pre-B cells and increases the 
expression of cyclin D1. Cyclin D1 drives the cell cycle thus promoting cell proliferation. 
This is believed to be the first oncogenic event in MCL. Additional oncogenic events are 
needed for MCL pathogenesis including aberrations in DNA-damage repair, cell cycle 
control and cell survival pathways. MCL is also dependent on the tissue microenvironment in 
order to survive, since MCL cells kept in vitro quickly die if not co-cultured with e.g. stromal 
cells.  
The typical MCL patient is male and 65-70 years old at the time of diagnosis. The disease is 
often spread to bone marrow, blood, lymph nodes, Waldeyers ring, gastro intestinal tract and 
spleen. MCL usually respond well to first line treatment but then invariably relapses. 
In my studies, I have used a well characterized population-based cohort of MCL patients 
from the Stockholm region. I have used this cohort to study various aspects of the disease, 
including potential markers to identify a more indolent disease course, the impact of the 
lymphoma tissue microenvironment and the cannabinoid receptors and the role of gender, 
comorbidities and choice of therapy in relation to outcome. 
In paper I and paper IV we identify a subpopulation of MCL patients with a more indolent 
disease course, not needing therapy for at least two years after diagnosis. Several studies have 
tried to find a good marker predicting indolent disease, and the transcription factor SOX11 
was initially suggested to carry such information. In paper I, we verify known prognostic 
markers such as age, elevated ECOG performance status, elevated lactate dehydrogenase 
(LDH) and high p53 expression, while SOX11 could not be used alone to predict disease 
course. In paper IV we found that women are older and more often have elevated LDH at the 
time of diagnosis. After introduction of the monoclonal CD20 antibody rituximab to first line 
therapy, the OS increased. In contrast to most studies we found that male gender was a 
positive prognostic factor. The median overall survival (OS) for all patients was 3,9 years and 
for those receiving or were intended for ASCT (27,3%) 16,3 years.  
In paper II we report that the tissue microenvironment in MCL correlate to patient outcome. 
In MCL samples, T cells were fewer than in reactive lymph nodes and higher CD4+/CD8+ 
ratio correlated to longer OS. 
In paper III we study the impact of the two cannabinoid receptors type 1 and type 2 (CB1 and 
CB2) which are upregulated in MCL cells compared to non-malignant B cells. We analysed 
CB1, CB2 and the enzymes involved in synthesis and metabolism of the cannabinoid 
receptor agonist anandamide (NAPEPLD and FAAH, respectively). All MCL had 
upregulated expression of NAPEPLD and most had low expression of FAAH compared to 
normal B cells thus favouring increased anandamide levels. Further, we found high 
expression of CB1 and high CB1 expression correlated to SOX11-positivity while low CB1 
expression correlated to leucocytosis and lymphocytosis. High amount of FAAH also 
correlated to leucocytosis and lymphocytosis and to p53-positivity. We found no prediction 
 
 
for outcome, but the endocannabinoid system is still a potential target for therapy that needs 
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1  B CELLS, INNATE AND ADAPTIVE IMMUNITY AND B 
CELL DEVELOPMENT 
1.1 BACKGROUND 
Mantle cell lymphoma (MCL), which is the topic of this thesis, is a B cell lymphoma. B cells 
are lymphocytes that are part of our adaptive immune system. Vertebrates have two main 
defence systems to protect our body against microbes, parasites and viruses; the innate and 
the adaptive immune system. The adaptive immune system consists of B cells and T cells and 
eliminates and/or stop the growth of viruses and bacteria that contain non-self-antigens and 
also creates a long-lived immunological memory that can be activated again, generating a 
quick response if the antigen is reintroduced. Our innate immune system is composed of 
several different immune cells such as macrophages, dendritic cells and granulocytes that via 
Toll-like receptors, phagocytosis and complement cascade try to eliminate an antigen if 
present for instance in a wound, as a foreign body or invading bacteria. The innate immune 
system does not have a long-term immunological memory, but it activates the adaptive 
immune system by presenting non-self-peptides to T and B cells. This can be done by antigen 
presenting cells (APC) that bind the antigen on HLA molecules, recognized by cells in the 
adaptive immune system that become activated [1]. B cells are derived from lymphoid 
progenitor cells that in turn are developed from hematopoietic stem cells. The lymphoid 
progenitor cell resides in our bone marrow. Via several transcription factors (EBF1, E2A, 
PAX5) the progenitor cell transits to a precursor and finally to a mature B cell. During this 
process the B cell needs to develop a unique and functioning B cell receptor (BCR) [2, 3]. 
Figure 1 shows the BCR that is a transmembrane receptor which on the extracellular site 
binds antigen and then transmits signals for B cell activation.  
Figure 1. Schematic picture of BCR with two heavy chains and two light chains and their constant and 































In MCL, BCR signalling is perturbed leading to the constitutive proliferation of the 
malignant cells [4]. The BCR is composed of an immunoglobulin molecule and several 
signalling molecules. The immunoglobulin can also be secreted by mature B cells and 
plasma cells. The immunoglobulin consists of two identical heavy chains and two identical 
light chains. The heavy chain and the light chain both have constant and variable regions, 
thus the number of different antibodies that can bind to different antigens are in theory 
innumerable. The heavy chain is formed with a first step by rearranging the antigen 
receptor genes at the D heavy (DH) and J heavy (JH) loci resulting in a DHJH joint and the 
cell is then called pro-B cell. Next step is for a V heavy (VH) locus to join the DHJH, 
resulting in an IG heavy chain that is paired to a temporary light chain. The BCR is now 
tested for its functional use. If the BCR is ok, then the light chain starts to form by 
rearranging VL and JL loci and is expressed as either k or l. Now we have an immature B 
cell [5-7]. To continue to become a mature naïve B cell, the BCR must not show any 
responsiveness to autoantigens. If so the BCR can undergo additional rearrangements of the 
light chain or the B cell is driven to an anergic state or apoptosis [3, 8]. The immature B 
cells leave the bone marrow (BM) and migrates to the spleen where they continue 
development and become naïve, follicular or marginal zone B cells. The marginal zone 
cells are our first line of defence to antigens circulating in the blood and when encountering 
an antigen, the marginal zone cell develops to extrafollicular plasma cells producing and 
secreting immunoglobulin (Ig) M. This type of response is known as a T cell-independent 
response [9]. In contrast, the T cell-dependent response takes place in germinal centres of 
the spleen and lymph nodes where the B cells develop to plasma cells or memory B cells 
(reviewed in) [10]. The memory B cells are able to survive in niches in the bone marrow for 
decades [11]. The interaction between B cells and T cells involves numerous receptors and 
signals, e.g. cluster of differentiation (CD)40-CD40-ligand, interleukin (IL)-21, IL-6 and 
inducible T cell co-stimulator (ICOS) and ICOS ligand (reviewed in) [12]. The B cells in 
the germinal centres also interact with follicular dendritic cells and form a light zone where 
the B cells (centrocytes) are loosely connected and expands, thus squeezing the residing B 
cells (centroblasts) to a compact, dark zone where B cells are rapidly proliferating and 
positioned densely. In the dark zone somatic hypermutations (SMH) can occur. SHM can 
be deletions, point mutations, duplications or insertions in the VH and may cause change in 
the BCR receptor affinity. This can be repeated several times towards getting the best BCR 
affinity possible for the specific antigen. In the mantle zone, which lays around the dark and 
light zones, but inside of the marginal zone of germinal centres, small and resting naïve B 
cells reside [10, 13, 14]. The centrocytes (B cells in the light zone of the germinal centre) 
can also undergo class switch. Their heavy chains constant region (CH) can be changed 
through class switch recombination. This results in deletion and replacements of genes 
coding for the constant region but no changes in the variable region. Thus, IgM and IgD 
isotypes can be switched to IgG, IgE or IgA. This will keep the affinity for the antigen 
through the variable region but will change the function of the antibodies [15, 16]. The B 
cells undergo further differentiation to plasma cells which secrete the antibody that through 
this whole process has been shown to have the best affinity for the antigen. The long-lived 
plasma cells reside in specific niches in the BM. Other B cells may differentiate towards 
memory B cells that leave the germinal centre and can be activated again for a quicker 






Figure 2. Normal B cell development and different B cell lymphomas. (Modified from Kuppers, R., 
Mechanisms of B cell lymphoma pathogenesis. Nat Rev Cancer, 2005) 
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1.2 BCR SIGNALLING 
The BCR is a transmembrane receptor on the surface of B lymphocytes. It consists of Igs and 
several accessory signal proteins for example CD79a and CD79b. Activation of the BCR 
upon binding to an antigen regulates, via downstream signalling, proliferation, metabolism, 
cytoskeleton remodelling, DNA repair and survival of the B cell [20]. This is executed via 
signalling cascades in the B cells membrane-proximal kinases e.g. Spleen tyrosine kinase 
(SYK), Bruton´s tyrosine kinase (BTK) and PI3K shown in Figure 3. These kinases also play 
a role in B cell migration and adhesion [21-23]. Downstream of these kinases, activation of 
e.g. Ras, mitogen-activated protein kinase (MAPK), nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) and other signalling proteins leads to regulation of the 
B cell´s survival [24]. Certain proteins in BCR signalling machinery are also targets for 
therapy e.g. the BTK inhibitor ibrutinib, successfully used in chronic lymphocytic leukaemia 











2   CANNABINOID RECEPTORS AND ENDOCANNABINOIDS 
The hemp plant, Cannabis Sativa contains more than 540 different chemical compounds 
and of those over 100 different cannabinoids. D9-tetrahydrocannabinol (THC) is the main 
biological component (reviewed in) [26].  Several endogenous cannabinoids have been 
discovered, the first do be described was an eicosanoid derivate, N-arachidonoyl 
ethanolamine, also called anandamide (AEA)  [27]. Others are e.g. 2-arachidonoyl glyceryl 
(2-AG) [28, 29]. The endocannabinoids are synthesized from cell membrane lipids when 
needed. Cells synthesizing endocannabinoids are e.g. lymphoid cells in peripheral blood, 
activated macrophages, microglia, tonsillar B cells, thrombocytes and sensory nerve fibres 
(reviewed in) [30]. Cannabinoids bind to the cannabinoid receptors, transmembral G-
protein coupled receptors. The two most studied cannabinoid receptors are cannabinoid 
receptor type 1 and type 2 (CB1 and CB2). CB1 was cloned from brain cells in 1990 and in 
1992 CB2 was cloned from an acute myeloid leukaemia (AML) cell line [31, 32].  The 
gene for CB1 is CNR1 located on chromosome 6 and CB2 is encoded by CNR2 located at 
chromosome 1. In non-malignant tissue CB1 is mostly expressed in neural cells and CB2 in 
immune cells. Mouse studies have shown that CB2 affects the release of immature B cells 
from the bone marrow and also plays a role for positioning of B cells in the spleen [33, 34].  
We and others have through gene expression profiling and PCR analysis of messenger 
ribonucleic acid (mRNA) shown that CB1 and CB2 are more highly expressed in MCL than 
in purified B cells or reactive lymphoid tissue [35-37]. Our group has also shown that 
synthetic cannabinoids can induce cell death in MCL in vitro and tumour growth reduction in 
















3   LYMPHOMAS, SUB CLASSIFICATION, CELL OF ORIGIN 
CONCEPT AND PATHOGENESIS 
Lymphomas are derived from T cells or B cells and B cell lymphomas are more common 
than T cell lymphomas. Lymphomas can be further divided into Hodgkin lymphoma (a B 
cell lymphoma) and non-Hodgkin lymphomas (NHL) (most B cell lymphomas and all T 
cell lymphomas) [39]. NHL constitutes ca 90% of all lymphomas and represent about 4 % 
of all malignancies in the US [40]. MCL counts for 4% of all lymphomas in the US and 7-
9% in Europe [41]. In Sweden we have an incidence of NHL of 21.6 men and 15.3 women 
per 100 000 persons and year [42].  
Lymphomas are often described as aggressive (rapid growth and spread with severe 
symptoms) or indolent (slow growth and spread with fewer symptoms) e.g. Burkitt 
lymphoma is an aggressive type and mucosa-associated lymphoid tissue (MALT) 
lymphoma is considered indolent [40]. Some lymphomas, such as MCL, can present with 
either an indolent or aggressive clinical course. Lymphomas can be further classified based 
on their resemblance to normal B cells, the so-called cell-of-origin classification, which is 
also the basis of the WHO classification of lymphoid malignancies. In this classification 
MCL bears resemblance to naïve B cells located in the mantle zone of B cell follicles.  
The majority of the B cell lymphomas resemble B lymphocytes in the germinal centre or 
later stages. This has been shown by examining e. g. B cell markers, gene expression 
patterns comparing lymphomas with purified normal B cell populations, somatic 
hypermutations and class switch recombination in the malignant B cell. It can be assumed 
that somatic hypermutation and class switch in the germinal centre generates errors in the 
DNA which leads to lymphoma development [17, 43]. These errors are usually eliminated, 
or the cell is designated for apoptosis thanks to several checkpoints. To reach full malignant 
status a B cell needs to fail in several normal security check points that normally controls 
proliferation and apoptosis. Many B cell lymphomas also have chromosomal translocations 
that dysregulates proto oncogenes. These translocations occur during V(D)J recombination 
and class switch [43]. This is the case in MCL where the cyclin D1 gene (CCND1) is 
translocated to the immunoglobulin heavy chain enhancer. Other examples of genes that are 
translocated in B cell lymphomas are BCL2, MYC and BCL6, [44-47]. However, in spite of 
translocations and gene mutations most lymphoma cells cannot survive without interaction 
with cells in the tissue microenvironment. Both CLL and MCL are lymphomas that mostly 
proliferate in BM and peripheral secondary lymphoid organs (SLO). In SLO they interact 
with CD4+ T cells, lymphoma associated macrophages and mesenchymal stroma cells for 
example as shown in Figure 4 [48, 49]. Furthermore, also viruses can be involved in 
lymphoma development. For example, Epstein-Barr virus has been connected to 
development of Burkitt lymphoma, DLBCL, Hodgkin lymphoma and posttransplant 
lymphoma (PTLD) [50-52]. Human herpesvirus 8 and hepatitis C virus can also drive 






Figure 4. MCL cell interacts with T cells, BCR, mesenchymal stroma cells (MSC) and lymphoma associated 




4  MANTLE CELL LYMPHOMA 
4.1 BACKGROUND 
When I first came in contact with MCL in 2003 it had been known as a specific entity for 
only 9 years. In 1994 it was defined as MCL [55, 56] but already in 1992 it was suggested 
that the earlier named intermediate lymphocytic lymphoma, mantle zone lymphoma, 
lymphocytic lymphoma of intermediate differentiation and centrocytic lymphoma was one 
entity [57]. When the gene translocation t(11;14) was discovered, the proposal for the new 
entity and the new name MCL instead of centrocytic lymphoma came. The name mantle cell 
lymphoma refers to their morphologic resemblance to mantle zone B cells (non-neoplastic 
counterpart), residing in the mantle zone of the follicle [58]. 
 
4.2 DISEASE DEVELOPMENT  
MCL is a  B-cell lymphoma constituting 5-10% of all lymphomas [39]. The first event in the 
pathogenesis of MCL is thought to be the gene translocation t(11;14) (q13;q33) which 
juxtaposes the gene CCND1, encoding the cell cycle regulator cyclin D1 to the 
immunoglobulin heavy chain (IGH) enhancer. This leads to overexpression of the protein 
cyclin D1. In some instances, the mRNA for cyclin D1 is truncated and lacks sequences that 
mediate mRNA turnover. This results in a mRNA that has a longer half time than normal one 
and elevated cyclin D1 protein to drive the cell cycle [59]. There is a subgroup of MCL that 
lack the t(11;14) translocation and cyclin D1 expression, but then they often instead express 
cyclin D2 or cyclin D3 [60, 61]. The mutational spectrum and gene expression profiles are 
similar in cyclin D1 positive and cyclin D1 negative MCL and these are therefore considered 
to be the same disease [62]. 
For MCL to develop, additional oncogenic events than the t(11;14) translocation are needed. 
The t(11;14) translocation occurs in pre-B cells in the BM but MCL is a mature B-cell 
lymphoma which suggests that the additional oncogenic events take place later in the B-cell 
development [63]. Those additional oncogenic aberrations have been shown to have impact 
on DNA damage repair, cell cycle control and cell survival pathways, e.g. p53, CDK4, BCL2 
and RB1 [64-66].  
Earlier it was believed that MCL arise from naïve B cells, but studies have shown that over 
40% of the MCLs have mutated Ig genes and others have Ig receptors that are biased and 
not randomly selected [67]. This indicates that the tumour cells might have been stimulated 
by antigen during the development of the disease [68]. The current hypothesis is that MCL 
arises from a pre-malignant condition where the cells have the t(11;14) but not the 
additional genetic lesions present in a fully developed lymphoma. 
Low levels of peripheral blood lymphocytes with the t(11;14) translocation have been 
identified in healthy patients as a sign of a premalignant condition. Similarly, few cyclin D1 
positive cells can occasionally be detected in the mantle zones of reactive lymphatic tissue 
(MCL in situ). The t(11;14) translocation is also, together with sex-determining region Y-box 
(SOX)11 positivity (discussed below), markers for finding minimal residual disease which 
could lead to relapse of the disease [69]. Interestingly a B cell subpopulation in tonsils 
believed to be the true counterpart to MCL has recently been identified [70]. In our cohort of 
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MCL patients we found 10 patients (5,9%) that had sole engagement of MCL in their tonsil at 
the time of diagnosis. There is also apprehension of subclinical engagement of MCL in this 
tissue and in the GI-tract, which might be the tissue of location for MCL origination and 
development [71]. Studies have shown that up to 30% of the MCL patients have symptoms 
from the GI-tract but when analysing tissue samples from macroscopically normal mucosa in 
MCL patients with or without gastro intestinal (GI) symptoms up to 80% of the patients have 
MCL engagement there[72-74]. Since GI engagement is not crucial for decisions regarding 
therapy it is not a standard procedure to investigate GI tract for possible MCL involvement. 
MCL have histologically three different growth patterns. MZ pattern, nodular (N) pattern and 
diffuse (D) pattern, which may carry information on the biology of the disease. The growth 
patterns have limited prognostic value as a single factor, further discussed below [75].  
 
4.3 DIAGNOSTIC PHENOTYPES 
MCL is routinely diagnosed using morphology, immunohistochemistry (IHC) on paraffin 
embedded tissue sections of e.g. lymph node or other lymphoid tissue and flow cytometry on 
cell suspensions from lymphoid tissue or bone marrow aspirates. Also fluorescent in situ 
hybridization (FISH) is used to detect the gene translocation t(11;14)(q13;q33). The most 
common immune phenotype is CD19+, CD20+, CD5+, CD22+, CD24+, CD79a+, CD43+, 
FMC7+ and BCL2+ and CD10-, CD11c-, CD23-, CD200- and BCL6- together with cyclin 
D1+ and SOX11+. However, variations exist: there are about 10% cyclin D1 negative (as 
mentioned earlier), 5% CD5 negative and 5-10% SOX11 negative MCL cases [76, 77], 
(reviewed in) [78]. 
 
4.4 CLINICAL PRESENTATION 
In Sweden approximately 100 new MCL cases per year are diagnosed and the median age at 
diagnosis is around 70 years but, in some parts of the world e.g. the US as low as 60 years 
[39, 79]. The larger portion are males and Caucasian. Increased risk of developing MCL is 
associated to ever living on a farm, having a family history of non-Hodgkin lymphoma or 
leukaemia and reduced risk is associated to having hay fever [80]. This indicates that MCL 
could be driven from environmental factors. However, risk factors for developing MCL are 
not alcohol or tobacco smoking as for most cancers. 
MCL is often widely spread at the time of diagnosis and found in BM, blood and extra 
nodal sites such as the spleen, Waldeyers ring and in the GI tract [81]. At the time of 
diagnosis, patients often have B-symptoms (fever, >10% weight loss for 6 months, night 
sweats, fatigue), palpable lymph nodes and sometimes splenomegaly [82]. Blood tests show 
in most cases as in our cohort (paper IV) no leukemic disease but when analysed by flow 






4.5 INDOLENT MCL 
There is a subpopulation of MCL patients that show a more indolent disease course and they 
do not require any therapy at the time of diagnosis, usually treatment can wait up to several 
years [84]. In the US deferred therapy for more than 90 days is considered to reflect an 
indolent disease course whereas in Sweden and other European countries deferred therapy for 
at least two years has been used to define indolent cases [85]. The decision to start treatment 
in the indolent patients of our cohort has been based on clinical parameters such as B-
symptoms, high lymphocytosis or large tumour burden or large infiltration in the BM. 
However, it is difficult to identify these patients at diagnosis, which implies risk for 
overtreatment. In order to find markers for these indolent cases it is important to investigate 
the pathogenesis and course of MCL. Lately it has been found that a combination of 
leukemic, non-nodal (or very little nodal engagement) disease with splenomegaly and bone 
marrow engagement of MCL in the patients predicts a more indolent course [39, 86]. 
Summarization of the usual characteristics of the classic (nodal) and non-nodal MCL is 




Classic (nodal) MCL Non-nodal MCL 
unmutated IGHV-regions mutated IGHV-regions 
SOX11-positive SOX11-negative 
involves lymph nodes non-nodal disease 
involves extra nodal sites 
e.g. GI-tract 
involves peripheral blood, 
bone marrow and spleen 
aggressive disease indolent disease 
Table 1. Characteristics of classic and non-nodal MCL as defined in WHO classification of tumours of 












4.6 THE ROLE OF THE MICROENVIRONMENT IN MCL PATHOGENESIS 
The surrounding cells of the MCL also seem to have importance for survival and evolvement 
of the lymphoma. This has been shown using CD40/ CD40 ligand (CD154) stimulation in 
which T cells interact with and affect the MCL cells [87]. Furthermore, a large number of 
macrophages are found in the microenvironment surrounding the MCL. It has been found 
that they correspond to more aggressive, high mitotic MCL disease [88]. Pro-proliferative 
signals increase the risk for further genetic aberrations in addition to t(11;14). Antigen 
stimulation could thus lead to transformation from indolent to aggressive MCL. This 
indicates that the microenvironment has impact on the development of MCL [89, 90]. 
In follicular lymphoma, patient survival has been found to be associated to molecular features 
of non-malignant cells in the tumour microenvironment [91-93].  
The microenvironment in the tissue of MCL contains various non-malignant cells such as T 
cells, macrophages and stromal cells which are important for growth stimulation and 
prevention of apoptosis of the MCL cells, thus the lymphoma cells are not autonomous, 
earlier shown in Figure 4. This was shown by Medina et al. where ex vivo isolated MCL cells 
kept in cell culture without any supportive cells had much shorter survival compared to MCL 
cells co-cultured with stromal cells, 2 weeks versus at least 7 months, respectively [94]. 
 
4.7 CLINICAL AND BIOLOGICAL PROGNOSTIC MARKERS 
Prognostic markers for MCL are desirable and some markers are discussed below. Among 
clinical prognostic markers the Mantle cell lymphoma International Prognostic Index (MIPI) 
is widely used [95]. MIPI includes age, lactate dehydrogenase (LDH), lymphocyte count and 
performance status according to Eastern Cooperative Oncology Group (ECOG). MIPI has 
been a controversial tool, but studies have shown good validity also with todays developed 
therapies including monoclonal antibodies [96]. Lately it has shown to be an even more 
precise tool when adding information about the proliferation, defined as a cut-off 30% IHC-
stained Ki-67 lymphoma cells, known as MIPI-c (combined). This resulted in four different 
risk groups with a range of 5-year overall survival (OS) from 17% to 85% [75].         
The tumour cell morphology may be associated to prognosis. In MCL there are several 
morphologic variants, such as a small cell variant, classic centrocytic variant and blastoid 
variant (BV). BV has a homogenous population of cells with blastoid or pleomorphic 
morphology, high number of genetic aberrations, high proliferation, often TP53 mutations 
and an aggressive clinical course [97, 98]. Also, the growth pattern of MCL has been 
discussed as prognostically relevant and is divided into three types, MZ, N and D growth 
pattern. These growth patterns showed to correlate to early or late stage of the disease and to 
be associated to survival [82, 99], though in later studies it has not on its own been shown to 
have prognostic value [75]. We analysed the growth patterns in our paper III but could not 
find statistically significant correlation to overall survival (OS). 
Genes that affect cell cycle control and transcription have been reported to carry prognostic 
information i.e. high expression of CCND1, high expression of MYC or MYC translocations, 
TP53 mutation or inactivation and high proliferation are all negative prognostic markers [62, 
100, 101]. TP53, a tumour suppressor gene often mutated in MCL, has been shown to be 
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associated to a more aggressive type of MCL and is an independent negative prognostic 
marker for the disease also in patients undergoing ASCT [102-107]. Mutations of the TP53 
gene often increase the expression of the protein p53 since the mutated protein is more stable 
and accumulate in the nucleus [108]. There are also novel tumour markers suggested to be 
associated to prognosis. For example, low absolute natural killer cell count in the peripheral 
blood in MCL patients has shown to be associated to inferior OS [109]. Also, a high degree 




The first SOX protein discovered was SRY (sex determining region on the Y chromosome) 
in 1990 and was the gene responsible for male differentiation on the Y chromosome 
ultimately differentiating Sertoli cells and testis development [111]. SRY proteins are only 
found in mammals and play a large role in cell differentiation [112]. In humans there are 20 
SOX proteins found [113]. They are a group of transcription factors that bind to DNA 
segments and are expressed during foetal life and involved in organogenesis [114]. 
Normal lymphocytes lack SOX11 expression while MCL highly expresses SOX11 in most of 
the cases (>90%) [115]. SOX11 has been shown to be involved in cell differentiation and 
neurogenesis in the central nervous system [116]. 
A previous study from our group, including 53 cases, showed that MCL patients with 
SOX11-negative tumours had shorter OS, which could indicate that SOX11 is of prognostic 
importance [117]. This study was small and later came contradicting studies from other 
groups indicating that SOX11-negative tumours were indolent [118]. Both the first study 
from our group and the later study from another group were based on a selected patient 
material, which is why we chose to investigate SOX11 in our unselected population-based 
cohort from the Stockholm area in paper I. After this, others confirmed our results [119] and 
it is now believed that SOX11 cannot predict outcome alone. However, there is a clinical 
pattern in some MCL patients with the non-nodal MCL described above that are usually 
SOX11-negative with a more indolent disease course [39, 119]. 
 
4.9 THE CHOICE OF THERAPY 
Conventional MCL therapy in patients below 70 years of age at diagnosis and with no 
comorbidities consists of chemotherapy e.g. cyclophosphamide, doxorubicin, vincristine, 
and prednisone (CHOP) with alternating cycles of cytarabine, both in combination with the 
monoclonal antibody rituximab (R) [120, 121]. This protocol called the Nordic protocol 
MCL2 was developed by the Nordic Lymphoma Group and several studies on this have 
been published [122-125]. This intense treatment combined with autologous stem cell 
transplantation (ASCT) has increased the median overall survival to close to 13 years [125]. 
Patients over the age of 70 mostly receive R-CHOP with rituximab maintenance or R-
bendamustine. When the disease is limited (Stage I and II with one to three adjacent lymph 
node territories) it is usual to treat this with only radiotherapy to the affected area [120]. 
Relapse therapy and therapy in chemotherapy refractive patients can be the above 
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mentioned in different combinations with the BTK-inhibitor Ibrutinib [126], (reviewed in) 
[127]. In patients with indolent disease presentation a watchful waiting approach is also 




























5  OVERALL AIM 
The aim of my thesis is to identify clinical and/or pathological markers that can predict 
outcome or serve as new potential targets for therapy in MCL in our population-based cohort. 
The studies include investigations of p53, SOX11, the effect of upregulated cannabinoid 
receptors, tumour growth patterns and proliferation and clinical variables such as stage and 
leukemic disease. Further we here investigate the importance of non-malignant cells in the 
microenvironment and their correlation to tumour features and prognosis. 
 
5.1 SPECIFIC AIMS 
Paper I: To investigate if SOX11can be used as a marker to identify aggressive or indolent 
disease in a population-based cohort. 
Paper II: To investigate the correlation of upregulated CB1, CB2 and the enzymes regulating 
the endocannabinoid anandamide in MCL to biological features of the disease.  
Paper III: To analyse the role of T cells in MCL patients as for tumour growth patterns and 
predict outcome. 
Paper IV: To analyse the clinical course, comorbidities, types of treatment and outcome of 















6  MATERIAL AND METHODS 
We retrieved all patients diagnosed with MCL according to the World Health Organization 
(WHO) classification from 1 of January 1998 to 31 of December 2013 at the Pathology 
Department, Karolinska University Hospital and S.t Görans Hospital, Stockholm. One 
experienced pathologist other than the one diagnosing reviewed all cases and verified the 
diagnosis. Clinical data was gathered from hospital charts. Flow cytometry analysis was 
performed as a diagnostic routine on lymph nodes and immunohistochemistry (IHC) staining 
was performed on paraffin-embedded diagnostic biopsies such as lymph node, BM, tonsil, 
spleen and extra nodal sites. RNA isolation, complementary deoxyribonucleic acid (cDNA) 
synthesis and quantitative polymerase chain reaction (qPCR) was performed as described in 
paper II. OS was calculated from time of diagnosis until time of death or last follow up and 
lymphoma specific survival (LSS) from time of diagnosis until time of MCL-associated death 
or last follow up. OS were calculated with Kaplan-Meier curves and log rank test. For 
comparison between groups we used t-test, multivariate analysis, Spearman test, Fishers 
exact test, Mann-Whitney-Wilcoxon test and logistic regression where needed.  P-value < .05 
was considered statistically significant. The analysis was made by a statistician in the first 
article and in the second and third by co-authors and the fourth by me with help from co-


















7  RESULTS AND DISCUSSION 
7.1 Paper I 
Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma  
The material comprised 186 MCL patients, diagnosed in the Stockholm area from January 1, 
1998 to June 30, 2010. The cases were retrieved through searching the pathology database 
Sympathy Pathology and the Regional Cancer Centre Registry. Clinical and pathological data 
was collected from charts and in paraffin embedded tumour tissue expression of p53, SOX11 
and the proliferation marker ki-67 was investigated by IHC.  
The cohort was studied with respect to indolent versus aggressive disease course by defining 
indolent as not requiring treatment during the first two years after diagnosis. 166 patients had 
aggressive and 17 had indolent disease, respectively. As expected, we found a statistically 
significant difference in presence of B-symptoms, proliferation (Ki-67>30%) and OS 
between the two groups. The median LSS time was not reached for the indolent MCL and 
was 3.1 year (1133 days) for the non-indolent MCL. As for earlier known prognostic markers 
such as CD23 expression on tumour cells, immunohistochemical p53 positivity and blastoid 
MCL we did not find any statistically significant difference between the indolent and non-
indolent groups. Of the indolent cases 15 out of 17 (88%) were SOX11 positive as well as 
142 out of 153 (93%) of the aggressive MCL. We also compared the SOX11 positive 
(n=160) and SOX11 negative (n=13) cases. Using univariate analysis, we found that 
expression of SOX11 was associated with longer OS and lack of SOX11 with shorter OS. 
Interestingly most SOX11 negative tumours expressed high levels of p53 protein, indicating 
mutated TP53. In multivariate analysis SOX11 did not remain a prognostic marker but p53, 
high LDH, ECOG>2 and age>65 did. In conclusion SOX11 cannot be used as a single 














7.2 Paper II 
Perturbations of the endocannabinoid system in mantle cell lymphoma  
In this study we analysed 107 samples of MCL; 100 from the time of diagnosis and 7 
relapses. Tissue samples of MCL tumour from lymph node (n=81), tonsil, spleen, GI-biopsies 
and cell suspensions of blood, BM and pleural fluid was used. As described earlier by our 
research group, the two cannabinoid receptors CB1 and CB2 are upregulated in MCL 
compared to non-malignant lymph nodes and purified non-malignant B cells and that 
exposure of cannabinoids to MCL induces cell death in vitro [35, 38]. The endocannabinoid 
system (ECS) consists of the endocannabinoids, the two receptors CB1 and CB2 and the 
enzymes regulating endocannabinoids´ levels. One of the major endocannabinoids is 
anandamide and its main synthesizing and metabolizing enzymes being N-acyl 
phosphatidylethanolamine phospholipase D (NAPEPLD) and fatty acid amide hydrolase 
(FAAH) respectively. Function of cannabinoid receptors and endocannabinoids have been 
reported to have an important role in other cancers e.g. gastric cancer, leukaemia and glioma  
[129-131], (reviewed in) [132, 133]. Therefore, we analysed the expression of CB1, CB2 and 
the synthesizing and metabolizing enzymes of anandamide in these 107 MCL patients. To 
investigate their importance and function we correlated the data to clinical and pathological 
features. By using qPCR analysis, we found that NAPEPLD was highly expressed in all 
MCL cases analysed but absent in normal B cells. Further the anandamide metabolizing 
enzyme FAAH was found to be upregulated only in 13 of the 107 MCL cases and 
downregulated in 95 (88%) cases. The gene for CB1 was overexpressed in 105 cases (98%) 
and CB2 was overexpressed in all cases compared to normal B cells. The mRNA levels of 
CNR1 and CNR2 correlated moderately. The upregulated expression of CB1, CB2 and 
FAAH was found to have no correlation to the amount of tumour cells of the cases as 
measured by flow cytometry. High FAAH was statistically significant correlated to anaemia, 
lymphocytosis, leucocytosis and p53-positivity. We found that low expression of CB1 was 
correlated to lymphocytosis, leucocytosis and high expression of CB1 was correlated to 
SOX11 positivity. High CB2 expression was only correlated to anaemia. Survival analysis 
did not show any significant difference with respect to CNR1, CNR2 nor FAAH expression. 
These results show that MCL cells would have an accumulation of the endocannabinoid 
anandamide. The low CB1 expression correlating to lymphocytosis could be explained by 
CB1 having effects on lymphocyte homing to lymphoid tissue. This is interesting since the 
MCL cells then lose their pro-survival signals from surrounding cells in the 
microenvironment of lymphatic tissue or bone marrow. Clinical studies of cancer treatment 









7.3 Paper III 
T-cell levels are prognostic in mantle cell lymphoma 
We hypothesized that MCL might be dependent on non-malignant cells in the tissue 
microenvironment.  In order to study this further, we analysed the frequency of non-
malignant T-cell and B-cells in diagnostic MCL lymph nodes by flow cytometry and related 
the findings to growth patterns, cell proliferation and clinical outcome. Flow cytometry data 
from all diagnostic lymph nodes (n=154) in our extended MCL cohort (including 244 patients 
diagnosed with MCL in the Stockholm region from January 1, 1998 to December 31, 2012) 
was evaluated. We analysed frequencies of tumour cells (based on MCL phenotype and 
expression of Ig light chains as a clonality marker), remaining normal B cells, CD3+ T cells 
and CD4/CD8 ratio.  Analysis of CD56+ natural killer (NK) cells and CD14+ 
monocytes/macrophages were done only in a subset of the diagnostic flow cytometry 
analyses and were therefore not included in the final analysis. Cell frequencies was expressed 
as percentage of cells in the mononuclear gate.  
Indolent disease was defined as above, not requiring treatment during the first two years after 
diagnosis. Higher CD4/CD8 ratio as a continuous variable was positively correlated to 
indolent disease and longer OS and negatively correlated to high tumour cell proliferation and 
higher p53 expression by IHC. Data are shown in Table 1 and 2 in paper III. The different 
growth patterns i.e. MZ, N and D growth pattern correlated to CD4/CD8 ratio and T cell 
percentage (Figure 1 and 2 in paper III) but not to OS. When analysing MCL grouped by 
growth pattern we found that indolent disease was statistically significant more common in 
MZ compared to D. In line with this, D had significantly more often elevated LDH, high 
proliferation and lymphocytosis than MZ. Further analysis also showed a statistically 
significant decrease in T cell frequencies and CD4/CD8 ratio during development from MZ 
growth pattern to D, mainly due to a reduction of CD4+ T cells (Table 2 in paper III). 
Comparison with reactive lymph nodes (n=26) showed that T cell frequencies in MZ were 
more similar to non-malignant lymphoid tissue (Figure 2 in paper III). In conclusion we have 
shown that the microenvironment of the normal lymph node is more preserved in indolent 
MCL and in MCL with MZ growth pattern. Higher CD4/CD8 ratio was positively correlated 
to indolent disease and longer OS and negatively correlated to high tumour cell proliferation. 
Since the CD4/CD8 ratio is independent of tumour burden (amount of tumour cells) and 
MCL cells earlier has shown to impair T cell responses [135], our results could indicate that 
MCL gradually progress towards being less dependent on signals from the microenvironment 
and/or that the immunological tumour control mechanisms are inactivated by lymphoma 









7.4 Paper IV 
Mantle cell lymphoma, a population-based long-term follow-up study on patients in the 
Stockholm region; clinical and pathological presentation, course and treatment. 
We have retrieved 258 patients diagnosed with MCL in the Stockholm area between January 
1, 1998 and December 31, 2013 and studied them regarding clinical and pathological 
parameters, treatment and disease course with long-term median follow-up of 3,9 years for all 
patients and 8,1 years for surviving patients. The majority of the patients were male (69,4%), 
older than 65 years (66%) and had stage IV disease (85,8%), SOX11 positivity (91,7%) and 
non-indolent disease (88,7%) at the time of diagnosis.  At the last follow-up 92,2% of the 
patients had received some kind of treatment, the most frequently being R-CHOP, CHOP, 
sole per oral alkylating agents, R-bendamustine and radiation therapy. In total, 27,3% of the 
treated patients were consolidated with ASCT. Median OS for the whole cohort was 3,9 years 
and for the patients treated with or intended for ASCT (thus receiving the same intense 
induction therapy) was 16,3 years. Patients before or during 2003, received rituximab more 
seldom as part of the treatment compared to patients treated after 2004, when rituximab was 
included in the Swedish treatment guidelines for MCL. Patients receiving rituximab had both 
statistically significant longer OS and LSS than patients not receiving rituximab as part of 
their first line treatment (OS 5,3 and 2,5 years, respectively and LSS 8,3 and 3,1 and years, 
respectively). Among our 258 MCL patients, 69 were diagnosed with another type of cancer 
before or after their MCL diagnosis, but only one case of therapy related myeloid malignancy 
and this after MCL treatment. In our cohort 28/254 patients had an indolent disease course, 
22 men and 6 women. As expected, the patients with indolent disease had at the time of 
diagnosis a less bulky tumour burden, fewer symptoms, less frequently blastoid variant and 
lower LDH levels than the non-indolent patients. Median OS for these patients was 6,9 years 
and median LSS was 11,5 years. Regarding gender differences, women were older than 
males at the time of diagnosis. There was no statistically significant difference between men 
and women as of clinical and pathological markers except for LDH-level that was higher in 
women. Neither time from diagnosis to treatment start, nor frequency of consolidation with 
ASCT, OS or LSS was statistically significantly different between the genders and OS and 
LSS were comparable. The rate of p53-positivity and SOX11-positivity was 17,7% and 
91,7% respectively, in line with other research groups results [119]. The treatment regimens 
and frequency of ASCT was also in concordance with a larger Swedish register study [79]. 
The monoclonal antibody rituximab often used in MCL therapy has different clearance in 
men and women. We investigated, but found no difference, in the male/female ratio of 
patients receiving or not receiving rituximab as part of their first line therapy. Due to their in 
average bigger body surface area men often receive a larger dose than women [136]. 
Although OS and LSS was similar in males versus females when analysed separately in those 
receiving rituximab-containing treatment, suggesting that also females receive an optimal 
dose of rituximab. 
Furthermore, we found male gender to be a positive prognostic factor for OS similar to 
Cohen et al. [85]. However, in most studies male gender is a negative marker for prognosis 
[85, 95, 137]. In conclusion we here show real-world data on non-selected population-based 
MCL patients with male gender being more frequent but surprisingly also a good prognostic 
factor. We showed that the women are older at the time of diagnosis and that they have 
higher LDH than men. We also showed that the use of rituximab after its inclusion in the 
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Swedish treatment guide lines doubled and also increased OS. Whereas we could not see that 































8  FUTURE PERSPECTIVES 
In further studies we hope to find new prognostic factors that correlate to indolent or 
aggressive disease. The importance of early knowledge of the disease course is essential in 
order to better select patients not in need of intense treatment at the time of diagnosis. Also 
new potential drugs and therapies are welcomed. CB1 and CB2 ligands being one path. Our 
research group has recently conducted one small clinical trials of clinically approved 
cannabinoids in leukemic, indolent lymphoma, and the results are currently analysed. 
Furthermore, chimeric antigen receptor T cell (CAR-T) treatment is already ongoing in other 
lymphomas targeting for example CD19 (reviewed in) [138]. Development of CAR-T that 
can target more than one CD is ongoing which would specify and narrow down the treatment 
even more, avoiding side effects [139]. To be able to combine several CDs in CAR-T could 
customize therapy in MCL. Another way of helping MCL patients survive is increased 
knowledge on how to avoid relapses. One could do that by studying how to find minimal 
residue disease (MRD) in the BM of the MCL treated patients who seem to be in complete 
remission [140]. These few MCL cells that compose the MRD are difficult to detect with 
conventional laboratory methods used to diagnose MCL such as immunohistochemistry and 
flow cytometry and highly sensitive PCR methods are needed. It has been discussed in 
studies that the most used qPCR analysis of t(11;14)(q13;q32) to find MRD could be 
inaccurate since other NHL also can have this translocation but that SOX11 might be a more 
specific marker [141, 142]. But then what about the SOX11-negative MCL cases? It would 
also be interesting collecting MCL MRD cells, analyse them regarding genetic and epigenetic 
changes and compare them to the patient´s diagnostic phenotype. This could be done with 
next-generation sequencing (NGS) of DNA. Maybe one might then find the differences that 
made these MRD cells survive the therapy given and find even other potential new targets of 
therapy.  
Since we found that higher CD4/CD8 T cell ratio was positively associated to indolent 
disease and longer OS and negatively correlated to high tumour cell proliferation one would 
also want to investigate which CD4+ T cell subsets there are in the MCL e.g. CD4+FOXP3+ 
and CD4+PD1+. The CD4+PD1+ T cells have shown to not respond to cytokines in follicular 
lymphoma and in tonsils [143]. Also, studies of MCL cells showed that the malignant cells in 
vitro efficiently inhibited CD4+ and CD8+ T cell proliferation and T cell–mediated cytolysis 
[135]. This together indicates that T cell signalling, and T cell responses could be important 
for the survival of the tumour cells. The immunomodulatory agent lenalidomide which has 
been showing good results in relapsed or refractory MCL through antitumor and 
antiproliferative effects is very interesting [144]. Lenalidomide can block angiogenesis and 
tumour cell proliferation and can stimulate T and NK cell-mediated cytotoxicity and increase 
the amount of NK cells (reviewed in) [145]. We believe that targeting or modifying the 
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